RELATED CONTENT
NEWS
- Australian panel recommends transparency overhaul at TGA
- NICE to review Fabre's Javlor again as comparison with unlicensed drugs deemed unfair
- In bone drug quandary, FDA seeks panel's advice on safety, 'drug holidays'
- Australia, New Zealand revive plans for joint regulator, first stage implementation imminent

